Please enable Javascript
TCT Meeting 2022 GVHD News
Minimum Residual Disease and Cytogenetic Persistence Prior to Hematopoietic Cell Transplant
Patrick Daly
Conferences
|
December 28, 2022
Researchers examined outcomes in peripheral blood haplo-HCT and their relation to pre-operation measurable residual disease.
Read More
Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil for GVHD Prevention
Patrick Daly
Conferences
|
December 28, 2022
The phase II study had enrolled 63 patients at the time of the interim analysis.
Read More
CD34+ Graft Cell Dose in Allogeneic Peripheral Blood Stem Cell Transplantation
Patrick Daly
Conferences
|
December 28, 2022
Venkata S. Thammineni, MD, and colleagues conducted a meta-analysis to assess the effect of graft CD on allo-PBSCT outcomes.
Read More
Antigen Profiles and MicroRNA Cargo as Biomarkers for Acute Graft-Versus-Host Disease
Patrick Daly
Conferences
|
December 28, 2022
Researchers examined the relationship between extracellular vesicle antigen expression and their microRNA cargo.
Read More
Identifying Biomarkers for Acute Graft-Versus-Host Disease Via Multiplex Proteomics
Patrick Daly
Conferences
|
December 28, 2022
The poster advanced a total of 27 "candidate protein biomarkers which may predict occurrence of aGVHD."
Read More
Abatacept for Graft-Versus-Host Disease Prevention in Pediatric Patients
Patrick Daly
Conferences
|
December 28, 2022
A studyobserved “encouragingly” positive results in reducing severe acute graft-versus-host disease (aGVHD).
Read More
Exploring Dose De-Escalation of Post-Transplant Cyclophosphamide
Patrick Daly
Conferences
|
December 28, 2022
The data were presented by the study’s lead author, Meredith Jo McAdams, MD, at the TCT 2022 Tandem Meetings.
Read More
Itolizumab for Newly Diagnosed Graft-Versus-Host Disease Treatment
Patrick Daly
Conferences
|
December 28, 2022
Researchers presented updated data from the phase Ib/II EQUATE trial.
Read More
Age and Mortality in Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease
Patrick Daly
Conferences
|
December 28, 2022
Researchers sought to characterize outcomes of pediatric patients who developed SR-aGVHD after allogeneic HSCT.
Read More
Clinical Outcomes and Economic Cost of Acute Graft-Versus-Host Disease in Germany
Patrick Daly
Conferences
|
December 28, 2022
A poster investigated the clinical outcomes in German patients who developed acute graft-versus-host disease.
Read More
Improving Graft-Versus-Host Disease Prevention After Haploidentical HSCT
Patrick Daly
Conferences
|
December 28, 2022
The study sought to improve graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplant.
Read More
Itacitinib for GVHD and CRS Prevention in Haploidentical Hematopoietic Cell Transplantation
Patrick Daly
Conferences
|
December 28, 2022
Researchers theorized that inhibiting JAK1 with itacitinib could prevent aGVHD and CRS in certain patients.
Read More
Outcomes in Treatment of Chronic Graft-Versus-Host Disease With Orca-T
Patrick Daly
Conferences
|
December 28, 2022
Orca-T appeared to yield a reduction in chronic graft-versus-host disease.
Read More
Innate Lymphoid Cells Mark Reduced Graft-Versus-Host Disease After Allogeneic Hematopoietic Grafts
Patrick Daly
Conferences
|
December 28, 2022
Researchers evaluated the presence of innate lymphoid cells in unmanipulated, lymphocyte-replete HCT grafts.
Read More
Failure-Free Survival After Belumosudil Therapy for Chronic Graft-Versus-Host Disease
Patrick Daly
Conferences
|
December 28, 2022
Researchers evaluated the rate of failure-free survival after belumosudil treatment for chronic graft-versus-host disease.
Read More
Plasma Vitamin E Levels Before Allogeneic Hematopoietic Cell Transplantation
Patrick Daly
Conferences
|
December 28, 2022
The investigators measured plasma vitamin E levels with high-performance liquid chromatography.
Read More
Advertisement
Advertisement